Page 1282 - Williams Hematology ( PDFDrive )

1256 Part IX: Lymphocytes and Plasma Cells Chapter 81: Hematologic Manifestations of Acquired Immunodeficiency Syndrome 1257

143. Dunleavy K, Pittaluga S, Shovlin M, et al: Low-intensity therapy in adults with Burkitt’s 171. Chen YB, Rahemtullah A, Hochberg E: Primary effusion lymphoma. Oncologist
lymphoma. N Engl J Med 369:1915–1925, 2013. 12:569–576, 2007.
144. Cortes J, Thomas D, Rios A, et al: Hyperfractionated cyclophosphamide, vincristine, 172. Bhatt S, Ashlock BM, Natkunam Y, et al: CD30 targeting with brentuximab vedotin:
doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients A novel therapeutic approach to primary effusion lymphoma. Blood 122:1233–1242,
with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. 2013.
Cancer 94:1492–1499, 2002. 173. Bhatt S, Ashlock BM, Toomey NL, et al: Efficacious proteasome/HDAC inhibitor com-
145. Wang ES, Straus DJ, Teruya-Feldstein J, et al: Intensive chemotherapy with cyclophos- bination therapy for primary effusion lymphoma. J Clin Invest 123:2616–2628, 2013.
phamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose 174. Zhou Z, Sehn LH, Rademaker AW, et al: An enhanced International Prognostic Index
cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab
lymphoma. Cancer 98:1196–1205, 2003. era. Blood 123:837–842, 2014.
146. Montoto S, Wilson J, Shaw K, et al: Excellent immunological recovery following 175. Biggar RJ, Jaffe ES, Goedert JJ, et al: Hodgkin lymphoma and immunodeficiency in
CODOX-M/IVAC, an effective intensive chemotherapy for HIV-associated Burkitt’s persons with HIV/AIDS. Blood 108:3786–3791, 2006.
lymphoma. AIDS 24:851–856, 2010. 176. Kowalkowski MA, Mims MP, Amiran ES, et al: Effect of immune reconstitution on the
147. Rodrigo JA, Hicks LK, Cheung MC, et al: HIV-Associated Burkitt Lymphoma: Good incidence of HIV-related Hodgkin lymphoma. PLoS One 8:e77409, 2013.
Efficacy and Tolerance of Intensive Chemotherapy Including CODOX-M/IVAC with or 177. Shiels MS, Koritzinsky EH, Clarke CA, et al: Prevalence of HIV Infection among U.S.
without Rituximab in the HAART Era. Adv Hematol 2012:735392, 2012. Hodgkin lymphoma cases. Cancer Epidemiol Biomarkers Prev 23:274–281, 2014.
148. Xicoy B, Ribera JM, Muller M, et al: Dose-intensive chemotherapy including rituxi- 178. Xicoy B, Ribera JM, Miralles P, et al: Results of treatment with doxorubicin, bleomy-
mab is highly effective but toxic in human immunodeficiency virus-infected patients cin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced
with Burkitt lymphoma/leukemia: Parallel study of 81 patients. Leuk Lymphoma 55: stage, human immunodeficiency virus-related Hodgkin’s lymphoma. Haematologica
2341–2348, 2014. 92:191–198, 2007.
149. Nagai H, Odawara T, Ajisawa A, et al: Whole brain radiation alone produces favourable 179. Montoto S, Shaw K, Okosun J, et al: HIV status does not influence outcome in patients
outcomes for AIDS-related primary central nervous system lymphoma in the HAART with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, ble-
era. Eur J Haematol 84:499–505, 2010. omycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era.
150. Newell ME, Hoy JF, Cooper SG, et al: Human immunodeficiency virus-related primary J Clin Oncol 30:4111–4116, 2012.
central nervous system lymphoma: Factors influencing survival in 111 patients. Cancer 180. Hasenclever D, Diehl V: A prognostic score for advanced Hodgkin’s disease. Inter-
100:2627–2636, 2004. national Prognostic Factors Project on Advanced Hodgkin’s Disease. N Engl J Med
151. Uldrick TS, Pipkin S, Scheer S, et al: Factors associated with survival among patients 339:1506–1514, 1998.
with AIDS-related primary central nervous system lymphoma. AIDS 28:397–405, 2014. 181. Hentrich M, Berger M, Wyen C, et al: Stage-adapted treatment of HIV-associated
152. Ammassari A, Cingolani A, Pezzotti P, et al: AIDS-related focal brain lesions in the era Hodgkin lymphoma: Results of a prospective multicenter study. J Clin Oncol 30:
of highly active antiretroviral therapy. Neurology 55:1194–1200, 2000. 4117–4123, 2012.
153. Bayraktar S, Bayraktar UD, Ramos JC, et al: Primary CNS lymphoma in HIV positive 182. Borchmann P, Skoetz N, Trelle S: BEACOPP or no BEACOPP?—Authors’ reply. Lancet
and negative patients: Comparison of clinical characteristics, outcome and prognostic Oncol 14:e488–e489, 2013.
factors. J Neurooncol 101:257–265, 2011. 183. Federico M, Bellei M, Cheson BD: BEACOPP or no BEACOPP? Lancet Oncol
154. Erdag N, Bhorade RM, Alberico RA, et al: Primary lymphoma of the central nervous 14:e487–e488, 2013.
system: Typical and atypical CT and MR imaging appearances. AJR Am J Roentgenol 184. Skoetz N, Trelle S, Rancea M, et al: Effect of initial treatment strategy on survival of
176:1319–1326, 2001. patients with advanced-stage Hodgkin’s lymphoma: A systematic review and network
155. Antinori A, De Rossi G, Ammassari A, et al: Value of combined approach with thal- meta-analysis. Lancet Oncol 14:943–952, 2013.
lium-201 single-photon emission computed tomography and Epstein-Barr virus DNA 185. Younes A, Connors JM, Park SI, et al: Brentuximab vedotin combined with ABVD or
polymerase chain reaction in CSF for the diagnosis of AIDS-related primary CNS lym- AVD for patients with newly diagnosed Hodgkin’s lymphoma: A phase 1, open-label,
phoma. J Clin Oncol 17:554–560, 1999. dose-escalation study. Lancet Oncol 14:1348–1356, 2013.
156. Lewitschnig S, Gedela K, Toby M, et al: F-FDG PET/CT in HIV-related central ner- 186. Re A, Cattaneo C, Michieli M, et al: High-dose therapy and autologous peripheral-
18
vous system pathology. Eur J Nucl Med Mol Imaging 40:1420–1427, 2013. blood stem-cell transplantation as salvage treatment for HIV-associated lymphoma in
157. Westwood TD, Hogan C, Julyan PJ, et al: Utility of FDG-PET CT and magnetic reso- patients receiving highly active antiretroviral therapy. J Clin Oncol 21:4423–4427, 2003.
nance spectroscopy in differentiating between cerebral lymphoma and non-malignant 187. Krishnan A, Molina A, Zaia J, et al: Durable remissions with autologous stem cell trans-
CNS lesions in HIV-infected patients. Eur J Radiol 82:e374–e379, 2013. plantation for high-risk HIV-associated lymphomas. Blood 105:874–878, 2005.
158. Jacomet C, Girard PM, Lebrette MG, et al: Intravenous methotrexate for primary cen- 188. Re A, Cattaneo C, Skert c, et al: Stem cell mobilization in HIV seropositive patients with
tral nervous system non-Hodgkin’s lymphoma in AIDS. AIDS 11:1725–1730, 1997. lymphoma. Haematologica 98:1762–1768, 2013.
159. Rubenstein JL, Gupta NK, Mannis GN, et al: How I treat CNS lymphomas. Blood 189. Diez-Martin JL, Balsalobre P, Re A, et al: Comparable survival between HIV+ and HIV-
122:2318–2330, 2013. non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral
160. Delecluse HJ, Anagnostopoulos I, Dallenbach F, et al: Plasmablastic lymphomas of the blood stem cell transplantation. Blood 113:6011–6014, 2009.
oral cavity: A new entity associated with the human immunodeficiency virus infection. 190. Krishnan A, Palmer JM, Zaia JA, et al: HIV status does not affect the outcome of autol-
Blood 89:1413–1420, 1997. ogous stem cell transplantation (ASCT) for non-Hodgkin lymphoma (NHL). Biol Blood
161. Carbone A, Gloghini A, Canzonieri V, et al: AIDS-related extranodal non-Hodgkin’s Marrow Transplant 16:1302–1308, 2010.
lymphomas with plasma cell differentiation. Blood 90:1337–1338, 1997. 191. Balsalobre P, Diez-Martin JL, Re A, et al: Autologous stem-cell transplantation in
162. Castillo J, Pantanowitz L, Dezube BJ: HIV-associated plasmablastic lymphoma: Lessons patients with HIV-related lymphoma. J Clin Oncol 27:2192–2198, 2009.
learned from 112 published cases. Am J Hematol 83:804–809, 2008. 192. Re A, Michieli M, Casari S, et al: High-dose therapy and autologous peripheral blood
163. Castillo JJ, Furman M, Beltran BE, et al: Human immunodeficiency virus-associated stem cell transplantation as salvage treatment for AIDS-related lymphoma: Long-term
plasmablastic lymphoma: Poor prognosis in the era of highly active antiretroviral ther- results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with
apy. Cancer 118:5270–5277, 2012. analysis of prognostic factors. Blood 114:1306–1313, 2009.
164. Schommers P, Wyen C, Hentrich M, et al: Poor outcome of HIV-infected patients with 193. Spitzer TR, Ambinder RF, Lee JY, et al: Dose-reduced busulfan, cyclophosphamide, and
plasmablastic lymphoma: Results from the German AIDS-related lymphoma cohort autologous stem cell transplantation for human immunodeficiency virus-associated
study. AIDS 27:842–845, 2013. lymphoma: AIDS Malignancy Consortium study 020. Biol Blood Marrow Transplant
165. Bibas M, Grisetti S, Alba L, et al: Patient with HIV-associated plasmablastic lymphoma 14:59–66, 2008.
responding to bortezomib alone and in combination with dexamethasone, gemcita- 194. Michieli M, Mazzucato M, Tirelli U, et al: Stem cell transplantation for lymphoma
bine, oxaliplatin, cytarabine, and pegfilgrastim chemotherapy and lenalidomide alone. patients with HIV infection. Cell Transplant 20:351–370, 2011.
J Clin Oncol 28:e704–e708, 2010. 195. Henrich TJ, Hu Z, Li JZ, et al: Long-term reduction in peripheral blood HIV type 1 res-
166. Saba NS, Dang D, Saba J, et al: Bortezomib in plasmablastic lymphoma: A case report ervoirs following reduced-intensity conditioning allogeneic stem cell transplantation.
and review of the literature. Onkologie 36:287–291, 2013. J Infect Dis 207:1694–1702, 2013.
167. Ammari ZA, Mollberg NM, Abdelhady K, et al: Diagnosis and management of primary 196. Hutter G, Zaia JA: Allogeneic haematopoietic stem cell transplantation in patients
effusion lymphoma in the immunocompetent and immunocompromised hosts. Thorac with human immunodeficiency virus: The experiences of more than 25 years. Clin Exp
Cardiovasc Surg 61:343–349, 2013. Immunol 163:284–295, 2011.
168. Boulanger E, Gerard L, Gabarre J, et al: Prognostic factors and outcome of human her- 197. Serrano D, Miralles P, Balsalobre P, et al: Graft-versus-tumor effect after allogeneic stem
pesvirus 8-associated primary effusion lymphoma in patients with AIDS. J Clin Oncol cell transplantation in HIV-positive patients with high-risk hematologic malignancies.
23:4372–4380, 2005. AIDS Res Hum Retroviruses 29:1340–1345, 2013.
169. Pan ZG, Zhang QY, Lu ZB, et al: Extracavitary KSHV-associated large B-Cell lym- 198. Dunleavy K, Wilson WH: How I treat HIV-associated lymphoma. Blood 119:3245–
phoma: A distinct entity or a subtype of primary effusion lymphoma? Study of 9 cases 3255, 2012.
and review of an additional 43 cases. Am J Surg Pathol 36:1129–1140, 2012. 199. Bower M, Collins S, Cottrill C, et al: British HIV Association guidelines for HIV-
170. Simonelli C, Spina M, Cinelli R, et al: Clinical features and outcome of primary effu- associated malignancies 2008. HIV Med 9:336–388, 2008.
sion lymphoma in HIV-infected patients: A single-institution study. J Clin Oncol 21: 200. Hentrich M, Hoffmann C, Mosthaf F, et al: Therapy of HIV-associated lymphoma-
3948–3954, 2003. recommendations of the oncology working group of the German Study Group of

Kaushansky_chapter 81_p1239-1260.indd 1257 9/21/15 11:19 AM